In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel
Michael Mazzeffi(University of Virginia), Jerrold H. Levy(Duke University), Kenichi A. Tanaka(University of Oklahoma Health Sciences Center), Atsuhiro Sugidachi(Daiichi Sankyo (United Kingdom)), Fania Szlam(Emory University), Joseph A. Jakubowski(Indiana Biosciences Research Institute)
Cited by 18
Related Papers
Guidelines for Perioperative Care in Cardiac Surgery
|JAMA Surgery|2019|1.2k
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
|New England Journal of Medicine|2017|1.1k
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
Patient Blood Management
|JAMA|2019|619